论文部分内容阅读
“7351”是由上海寄生虫病研究所于1970年合成的一种新抗疟药,系采用苯骈萘啶为母核,将双边的四氢吡咯次甲基支链与其相连,形成一种新的苯骈萘啶衍生物,化学名为2-甲氧基-7-氯-10[3,5-双四氢吡咯次甲基-4-羟苯基]氨基苯骈[1,5]-萘啶,商品名为磷酸咯萘啶,简称“7351”。近年来经初步在云南、广东海南岛、浙江、山东等地,对恶性疟疾及间日疟疾进行了现场观察,疗效迅速,副反应轻,与氯喹无交叉抗药性。1974年6～10月,山东省寄生虫病防治所在巨野县城关公社朱庄大队,应用“7351”针剂治疗间日疟36例,60天累计复发18例(复发率50％)复发
“7351” is a new antimalarial drug synthesized by the Shanghai Institute of Parasitic Diseases in 1970. It uses benzidine naphthyridine as the mother nucleus, and links bilateral tetrahydropyrrolidine methine branches to form a The new benzalkonium naphthyridine derivative has the chemical name of 2-methoxy-7-chloro-10 [3,5-bistetrahydropyrrolidinomethyl-4-hydroxyphenyl] aminobenzo [1,5] - naphthyridine, trade name phosphoric acid pyronaphthyridine, referred to as “7351”. In recent years, initially conducted in Yunnan, Guangdong, Hainan Island, Zhejiang, Shandong and other places on the malaria and malaria were observed on the spot, with rapid response, side effects, and chloroquine no cross-resistance. From June to October 1974, Zhuzhuang Brigade, Chengguan Commune, Juye County, Shandong Province, where parasitic diseases were controlled, 36 cases of Vivax malaria were treated with “7351” injection and relapse occurred in 18 cases (recurrence rate 50%) in 60 days